Study Summary
This trial is testing whether early lower extremity CIPN symptoms can predict which cancer patients being treated with neurotoxic chemotherapy are at risk for falling.
- Chemotherapy-induced Peripheral Neuropathy
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
2 Primary · 0 Secondary · Reporting Duration: Through study completion, up to 6 months
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
1 Treatment Group
mEMA Arm
1 of 1
Experimental Treatment
40 Total Participants · 1 Treatment Group
Primary Treatment: Mobile Ecological Momentary Assessment · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What is the total number of participants involved in this trial?
"Affirmative, the clinicaltrials.gov page shows that this medical trial is recruiting participants at present. This clinical experiment was first advertised on March 1st 2022 and has since been updated April 8th 2022. Currently, 40 patients are needed to take part in the study from one location." - Anonymous Online Contributor
Are there any available patient positions in this experiment?
"As per information located on the clinicaltrials.gov website, this medical trial is open for enrollment. The initial posting date was January 3rd 2022 and the most recent update was published April 8th 2022." - Anonymous Online Contributor